

## BILE SALTS

### Requirements for Prior Authorization of Bile Salts

#### A. Prescriptions That Require Prior Authorization

Prescriptions for Bile Salts that meet any of the following conditions must be prior authorized:

1. A prescription for a non-preferred Bile Salt, regardless of the quantity prescribed. See Preferred Drug List (PDL) for the list of preferred Bile Salts at: <https://papdl.com/preferred-drug-list>.
2. A prescription for Cholbam (cholic acid).

#### B. Clinical Review Guidelines and Review of Documentation for Medical Necessity

In evaluating a request for prior authorization of a prescription for a non-preferred Bile Salt, the determination of whether the requested prescription is medically necessary will take into account the following:

1. Whether the recipient has a documented history of therapeutic failure, intolerance, or contraindication of the preferred Bile Salts
2. For Cholbam (cholic acid) whether the recipient:
  - a. Is prescribed Cholbam (cholic acid) by or in consultation with a hepatologist or pediatric gastroenterologist

**AND**

- b. Is being treated for a condition that is:
  - i. U.S. Food and Drug Administration (FDA) approved, or a medically accepted indication

**AND**

- ii. Documented by medical history and laboratory results

**AND**

- c. Will have AST, ALT, GGT, alkaline phosphatase, bilirubin and INR monitored according to prescribing information
3. For Ocaliva (obeticholic acid), whether the recipient:
  - a. Is prescribed Ocaliva (obeticholic acid) by or in consultation with a hepatologist or gastroenterologist

b. Is being treated for a diagnosis that is:

- i. Indicated in the FDA-approved package insert OR a medically-accepted indication

**AND**

- ii. Documented by medical history and laboratory results

**AND**

- c. Has documented baseline liver function tests, including AST, ALT, GGT, alkaline phosphatase, bilirubin, and INR

**AND**

- d. Has a documented baseline HDL-C

**AND**

- e. Has a documented history of therapeutic failure of optimally-titrated doses of ursodeoxycholic acid (UDCA)

**AND**

- f. Will be prescribed Ocaliva (obeticholic acid) in combination with UDCA

**OR**

- g. Has a contraindication or intolerance of UDCA

**OR**

- 4. Whether the recipient does not meet the clinical review guidelines listed above, but, in the professional judgment of the physician reviewer, the services are medically necessary to meet the medical needs of the recipient.

**FOR RENEWALS OF PRESCRIPTIONS FOR CHOLBAM (CHOLIC ACID):** The determination of medical necessity of requests for prior authorization of renewals of prescriptions for Cholbam (cholic acid) that were previously approved will take into account whether the recipient:

- 1. Has documented improvement in liver function within the first 3 months of treatment

**AND**

- 2. Has documented AST, ALT, GGT, alkaline phosphatase, bilirubin and INR monitoring as recommended per prescribing information

**AND**

3. Does not have complete biliary obstruction, persistent clinical or laboratory indicators of worsening liver function or cholestasis.

FOR RENEWALS OF PRESCRIPTIONS FOR OCALIVA (OBETICHOLIC ACID): The determination of medical necessity of requests for prior authorization of renewals of prescriptions for Ocaliva (obeticholic acid) that were previously approved will take into account whether the recipient:

1. Has documented monitoring of liver function tests, including AST, ALT, GGT, alkaline phosphatase, bilirubin, and INR, since starting Ocaliva (obeticholic acid) and within the past six (6) months

**AND**

2. Has documentation of a positive response to Ocaliva (obeticholic acid) as evidenced by liver function tests

**AND**

3. Has documentation of recent HDL-C monitoring

**AND**

4. Does not have complete biliary obstruction

**OR**

5. Does not meet the clinical review guidelines listed above, but, in the professional judgment of the physician reviewer, the services are medically necessary to meet the medical needs of the recipient.

C. Clinical Review Process

Prior authorization personnel will review the request for prior authorization and apply the clinical guidelines in Section B above, to assess the medical necessity of the request for a prescription for a non-preferred Bile Salt. If the guidelines in Section B are met, the reviewer will prior authorize the prescription. If the guidelines are not met, the prior authorization request will be referred to a physician reviewer for a medical necessity determination. Such a request for prior authorization will be approved when, in the professional judgment of the physician reviewer, the services are medically necessary to meet the medical needs of the recipient.

## CHOLBAM (cholic acid) PRIOR AUTHORIZATION FORM

PRIOR AUTHORIZATION REQUEST INFORMATION			PRESCRIBER INFORMATION	
<input type="checkbox"/> New request	<input type="checkbox"/> Additional info	# of pages in request: _____	Prescriber name: _____	
<input type="checkbox"/> Renewal request	PA#: _____	_____		
Name of office contact: _____			Specialty: _____	
Contact's phone number: _____			State license #: _____	
LTC facility contact/phone: _____			NPI: _____	MA Provider ID#: _____
RECIPIENT INFORMATION			Street address: _____	
Recipient name: _____			Suite #: _____	City/state/zip: _____
Recipient ID#: _____	DOB: _____	Phone: _____	Fax: _____	
Medication will be billed via: <input type="checkbox"/> Pharmacy <input type="checkbox"/> Medical (Jcode: _____)			Place of Service: <input type="checkbox"/> Hospital <input type="checkbox"/> Provider's Office <input type="checkbox"/> Home <input type="checkbox"/> Other	

### CLINICAL INFORMATION

Drug requested: Cholbam capsule	Strength: _____	Quantity: _____
Directions: _____		Refills: _____
Diagnosis: _____		Dx code (required): _____

#### Section A: Initial Cholbam requests

1. If prescriber is NOT a hepatologist or pediatric gastroenterologist, is the requested medication being prescribed in consultation with one of the above specialists?	<input type="checkbox"/> Yes – <u>submit documentation of consultation</u> <input type="checkbox"/> No or not applicable
2. Does the Recipient have one of the following diagnoses? <input type="checkbox"/> bile acid synthesis disorder (BASD) due to a single enzyme defect (SED) <input type="checkbox"/> peroxisomal disorder (PD) (including Zellweger spectrum disorder)	<input type="checkbox"/> Yes – <u>submit results and dates of mass spectrometry or other biochemical or genetic testing</u> <input type="checkbox"/> No – <u>submit documentation supporting the use of Cholbam for Recipient's diagnosis</u>
3. <u>For a diagnosis of peroxisomal disorder</u> , will Cholbam be used in addition to other therapy/treatment?	<input type="checkbox"/> Yes – <u>submit documentation of concurrent therapy or treatment</u> <input type="checkbox"/> No
4. Does the Recipient have results of the following baseline (before starting Cholbam) lab tests? <input type="checkbox"/> AST <input type="checkbox"/> GGTP <input type="checkbox"/> bilirubin <input type="checkbox"/> ALT <input type="checkbox"/> alkaline phosphatase <input type="checkbox"/> INR	<input type="checkbox"/> Yes – <u>submit results and dates of all lab monitoring for all requested values</u> <input type="checkbox"/> No

#### Section B: Renewal Cholbam requests

1. Does the recipient have documentation of the following lab results since starting Cholbam and within the past 6 months? <input type="checkbox"/> AST <input type="checkbox"/> GGT <input type="checkbox"/> bilirubin <input type="checkbox"/> ALT <input type="checkbox"/> alkaline phosphatase <input type="checkbox"/> INR	<input type="checkbox"/> Yes – <u>submit results and dates of all lab monitoring for all requested values</u> <input type="checkbox"/> No
2. Has the Recipient shown clinical signs or symptoms or lab indicators of any of the following since starting Cholbam? <input type="checkbox"/> complete biliary obstruction <input type="checkbox"/> persistent or ongoing worsening of liver function <input type="checkbox"/> persistent or ongoing cholestasis	<input type="checkbox"/> Yes <u>Submit medical record</u> <input type="checkbox"/> No <u>documentation of clinical monitoring</u>
3. <u>For the FIRST RENEWAL REQUEST after starting or restarting Cholbam</u> , has the Recipient experienced an improvement in liver function within the first 3 months of treatment?	<input type="checkbox"/> Yes – <u>submit results and dates of baseline LFTs and LFTs drawn 3 months after starting/restarting Cholbam</u> <input type="checkbox"/> No

**PLEASE FAX COMPLETED FORM TO HIGHMARK WHOLECARE – PHARMACY DIVISION**

Prescriber Signature: _____	Date: _____
-----------------------------	-------------

**Confidentiality Notice:** The documents accompanying this telecopy may contain confidential information belonging to the sender. The information is intended only for the use of the individual named above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or taking of any telecopy is strictly prohibited.

## OCALIVA (obeticholic acid) PRIOR AUTHORIZATION FORM

PRIOR AUTHORIZATION REQUEST INFORMATION			PRESCRIBER INFORMATION		
<input type="checkbox"/> New request <input type="checkbox"/> Renewal request		Total # of pages: _____	Prescriber name:		
Name of office contact:			Specialty:		
Contact's phone number:			State license #:		
LTC facility contact/phone:			NPI:	MA Provider ID#:	
BENEFICIARY INFORMATION			Street address:		
Beneficiary name:			Suite #:	City/state/zip:	
Beneficiary ID#:	DOB:	Phone:	Fax:		
Medication will be billed via: <input type="checkbox"/> Pharmacy <input type="checkbox"/> Medical (Jcode: _____)			Place of Service: <input type="checkbox"/> Hospital <input type="checkbox"/> Provider's Office <input type="checkbox"/> Home <input type="checkbox"/> Other		

### CLINICAL INFORMATION

Drug requested:    Ocaliva tablet	Strength:	Quantity:
Directions:		Refills:
Diagnosis:		Dx code (required):

**Specialty Pharmacy Drug Program:** Ocaliva is part of the DHS Specialty Pharmacy Drug Program and is only available from one of the two DHS specialty pharmacies – Walgreen's Specialty Pharmacy.

#### Initial Ocaliva requests

5. If prescriber is NOT a hepatologist or gastroenterologist, is the requested medication being prescribed in consultation with one of the above specialists?	<input type="checkbox"/> Yes – <i>Submit documentation of consultation.</i> <input type="checkbox"/> No or not applicable
6. Does the beneficiary have a diagnosis of primary biliary cholangitis (PBC)?	<input type="checkbox"/> Yes – <i>Submit documentation of lab results and medical history supporting diagnosis.</i> <input type="checkbox"/> No – <i>Submit documentation supporting the use of Ocaliva for beneficiary's diagnosis.</i>
7. Does the beneficiary have results of the following baseline (before starting Ocaliva) lab results? <input type="checkbox"/> AST <input type="checkbox"/> GGTP <input type="checkbox"/> bilirubin <input type="checkbox"/> HDL-C <input type="checkbox"/> ALT <input type="checkbox"/> alkaline phosphatase <input type="checkbox"/> INR	<input type="checkbox"/> Yes – <i>Submit results and dates of all lab monitoring for all requested values.</i> <input type="checkbox"/> No
8. Does the beneficiary have a history of trial and failure, contraindication, or intolerance of ursodiol (ursodeoxycholic acid or UDCA)?	<input type="checkbox"/> Yes – <i>Submit all supporting documentation of trial and failure (including doses tried), contraindications, or intolerances with ursodiol.</i> <input type="checkbox"/> No
9. Will the beneficiary be taking Ocaliva in combination with ursodiol?	<input type="checkbox"/> Yes <i>Submit documentation of planned treatment regimen.</i> <input type="checkbox"/> No

#### Renewal Ocaliva requests

10. Does the beneficiary have documentation of the following lab results since starting Ocaliva and within the past 6 months? <input type="checkbox"/> AST <input type="checkbox"/> GGT <input type="checkbox"/> bilirubin <input type="checkbox"/> HDL-C <input type="checkbox"/> ALT <input type="checkbox"/> alkaline phosphatase <input type="checkbox"/> INR	<input type="checkbox"/> Yes – <i>Submit results and dates of all lab monitoring for all requested values.</i> <input type="checkbox"/> No
11. Has the beneficiary shown clinical signs or symptoms or lab indicators of complete biliary obstruction since starting Ocaliva?	<input type="checkbox"/> Yes <i>Submit documentation of clinical monitoring.</i> <input type="checkbox"/> No

### PLEASE FAX COMPLETED FORM TO HIGHMARK WHOLECARE – PHARMACY DIVISION

Prescriber Signature:	Date:
-----------------------	-------

**Confidentiality Notice:** The documents accompanying this telecopy may contain confidential information belonging to the sender. The information is intended only for the use of the individual named above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or taking of any telecopy is strictly prohibited.